Advanced Solid Tumors, Malignant Melanoma
Conditions
Brief summary
This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.
Interventions
DRUGAMT-253 for injection
Administered intravenously
Sponsors
Multitude Therapeutics Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Patients must be willing and able to understand and sign the ICF, and to adhere to the study visit schedule and other protocol requirements. * 2\. Patients with histologically confirmed melanoma or other advanced solid tumor. * 3\. Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease (PD) during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy. * 4\. Patients must have at least one measurable lesion as per RECIST version 1.1. * 5\. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * 6\. Life expectancy ≥ 3 months. * 7\. Patients must have adequate organ function * 8\. Women of child bearing potential (WCBP), defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally postmenopausal for at least 12 consecutive months must agree to use two effective contraceptive methods while on study treatment and for at least twelve weeks after the last dose of the IMP. * 9\. WCBP must have a negative serum pregnancy test within 7 days prior to first dose of the IMP. * 10\. Male patients must agree to use a latex condom, even if they had a successful vasectomy, while on study treatment and for at least twelve weeks after the last dose of the IMP. * 11\. Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 12 weeks after the last dose of the IMP. * 12\. Availability of tumor tissue sample at screening.
Exclusion criteria
* 1\. Prior treatment with any agent that has the same target. * 2\. Central nervous system (CNS) metastasis. * 3\. Active or chronic skin disorder requiring systemic therapy. * 4\. History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome. * 5\. Persistent toxicities from previous systemic anti-neoplastic treatments of Grade \>1. * 6\. Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP. * 7\. Major surgery within 28 days prior to first dose of the IMP, or no recovery from side effects of such intervention. * 8\. Significant cardiac disease, such as recent myocardial infarction or acute coronary syndromes, congestive heart failure， uncontrolled hypertension, uncontrolled cardiac arrhythmias. * 9\. History of thromboembolic or cerebrovascular events, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis, or pulmonary emboli within six months prior to first dose of the IMP. * 10\. Acute and/or clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV). * 11\. Administration of a live vaccine within 28 days prior to the administration of the first dose of the IMP.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DLTs | 21 days after first dose | Incidence of dose limiting toxicities |
| AEs | Up to 24 months | Type, incidence and severity of Adverse Events |
| SAEs | Up to 24 months | Type, incidence and severity Serious Adverse Events (SAEs) |
| ORR | Up to 24 months | Overall response rate assessed by the investigator according to RECIST version 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | Up to 24 months | aximum concentration (Cmax) |
| ADAs | Up to 24 months | Specification and quantification of anti-drug antibodies |
| Tmax | Up to 24 months | time to peak drug concentration |
| AUC | Up to 24 months | Area Under the Curve |
| t1/2 | Up to 24 months | terminal half-life of the ADC, total antibody and free payload |
Countries
China
Contacts
Primary ContactMinqi Guan
Outcome results
None listed